|
Nov 13
|
We're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
|
|
Oct 3
|
Independent Director of Biomea Fusion Michael J. Hitchcock Buys 200% More Shares
|
|
Oct 1
|
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
|
|
Sep 27
|
FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate
|
|
Sep 27
|
Biomea’s stock bounces back as FDA lifts clinical hold on diabetes trials
|
|
Sep 27
|
BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies
|
|
May 2
|
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
|
|
Apr 1
|
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
|
Apr 1
|
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
|
|
Apr 1
|
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
|
|
Mar 7
|
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
|
|
Mar 6
|
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
|
|
Jan 9
|
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 11
|
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ...
|
|
Dec 9
|
Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
|
|
Dec 8
|
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Res...
|
|
Dec 7
|
Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular ...
|
|
Dec 5
|
Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes
|
|
Aug 23
|
11 Best High Short Interest Stocks To Buy Now
|
|
Jun 26
|
Biomea Fusion Stock Is Trading Higher Today - Here's Why
|